Agilent Technologies (NYSE:A) Price Target Cut to $160.00 by Analysts at JPMorgan Chase & Co.

Agilent Technologies (NYSE:A) had its price target decreased by equities researchers at JPMorgan Chase & Co. from $165.00 to $160.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 24.47% from the company’s current price.

A has been the subject of a number of other reports. Wells Fargo & Company began coverage on shares of Agilent Technologies in a report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price objective for the company. TD Cowen boosted their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Bank of America increased their price objective on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Stifel Nicolaus reissued a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. Finally, Barclays increased their price target on Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $144.71.

Agilent Technologies Price Performance

Shares of A opened at $128.54 on Tuesday. The business’s 50 day moving average price is $137.82 and its two-hundred day moving average price is $137.54. The firm has a market cap of $36.93 billion, a PE ratio of 27.18, a price-to-earnings-growth ratio of 5.89 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. Agilent Technologies has a 52-week low of $124.10 and a 52-week high of $155.35.

Insider Buying and Selling at Agilent Technologies

In related news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. This trade represents a 19.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Institutional Investors Weigh In On Agilent Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Menard Financial Group LLC lifted its holdings in Agilent Technologies by 1.6% in the 2nd quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock worth $628,000 after buying an additional 77 shares during the period. McAdam LLC boosted its holdings in Agilent Technologies by 3.1% in the third quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after acquiring an additional 77 shares in the last quarter. Brown Brothers Harriman & Co. increased its position in Agilent Technologies by 13.5% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 77 shares during the period. Global Retirement Partners LLC lifted its position in shares of Agilent Technologies by 3.2% in the 3rd quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock worth $382,000 after purchasing an additional 79 shares during the period. Finally, Rovin Capital UT ADV boosted its stake in shares of Agilent Technologies by 1.6% during the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after purchasing an additional 81 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.